NCT04077463 2026-03-17Chrysalis-2Janssen Research & Development, LLCPhase 1 Active not recruiting701 enrolled
NCT02609776 2026-01-16CHRYSALISJanssen Research & Development, LLCPhase 1 Active not recruiting751 enrolled 1 FDA
NCT05395052 2023-09-21FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid TumorsFate TherapeuticsPhase 1 Terminated5 enrolled